Generic Arakoda Availability
Last updated on May 7, 2025.
Arakoda is a brand name of tafenoquine, approved by the FDA in the following formulation(s):
ARAKODA (tafenoquine succinate - tablet;oral)
-
Manufacturer: 60 DEGREES PHARMS
Approval date: August 8, 2018
Strength(s): EQ 100MG BASE [RLD]
Is there a generic version of Arakoda available?
No. There is currently no therapeutically equivalent version of Arakoda available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arakoda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Patent 10,342,791
Issued: July 9, 2019
Inventor(s): Smith; Bryan L et al.
Assignee(s): 60 Degrees Pharmaceuticals LLC (Washington, DC); The United States Of America As Represented By The Secretary Of The Army (Washington, DC)Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects. ##STR00001##
Patent expiration dates:
- December 2, 2035✓
- December 2, 2035
-
Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Patent 10,888,558
Issued: January 12, 2021
Inventor(s): Dow; Geoffrey S. et al.
Assignee(s): 60 Degrees Pharmaceuticals LLC (Washington, DC); The Government Of The United States As Represented By The Secretary Of The Army (Fort Detrick, MD)Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects. ##STR00001##
Patent expiration dates:
- December 2, 2035✓
- December 2, 2035
-
Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
Patent 11,744,828
Issued: September 5, 2023
Inventor(s): Dow; Geoffrey S. et al.
Assignee(s): 60 Degrees Pharmaceuticals LLC (Washington, DC); The Government Of The United States As Represented By The Secretary Of The Army (Fort Detrick, MD)Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects. ##STR00001##
Patent expiration dates:
- December 2, 2035✓
- December 2, 2035
More about Arakoda (tafenoquine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimalarial quinolines
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.